Arcus Biosciences Cash on Hand 2017-2023 | RCUS
Arcus Biosciences cash on hand from 2017 to 2023. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Arcus Biosciences Annual Cash on Hand
(Millions of US $) |
| 2022 |
$1,009 |
| 2021 |
$499 |
| 2020 |
$729 |
| 2019 |
$188 |
| 2018 |
$257 |
| 2017 |
$176 |
| 2016 |
$ |
Arcus Biosciences Quarterly Cash on Hand
(Millions of US $) |
| 2023-03-31 |
$954 |
| 2022-12-31 |
$1,009 |
| 2022-09-30 |
$1,049 |
| 2022-06-30 |
$1,173 |
| 2022-03-31 |
$1,214 |
| 2021-12-31 |
$499 |
| 2021-09-30 |
$525 |
| 2021-06-30 |
$721 |
| 2021-03-31 |
$827 |
| 2020-12-31 |
$729 |
| 2020-09-30 |
$782 |
| 2020-06-30 |
$462 |
| 2020-03-31 |
$158 |
| 2019-12-31 |
$188 |
| 2019-09-30 |
$191 |
| 2019-06-30 |
$224 |
| 2019-03-31 |
$242 |
| 2018-12-31 |
$257 |
| 2018-09-30 |
$258 |
| 2018-06-30 |
$266 |
| 2018-03-31 |
$280 |
| 2017-12-31 |
$176 |
| 2017-09-30 |
|
| 2017-06-30 |
|
| 2017-03-31 |
|
| 2016-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.536B |
$0.112B |
|
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
|
